Boosting engineered T cells

See allHide authors and affiliations

Science  12 Jul 2019:
Vol. 365, Issue 6449, pp. 119-120
DOI: 10.1126/science.aax6331

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


After decades of work, researchers have finally begun to see broadly reproducible success of engineered T cells in the treatment of cancer. Chimeric antigen receptors (CARs) are synthetic molecules that combine the antigen specificity of monoclonal antibodies with the signaling of the T cell receptor (TCR) to direct patient-derived (autologous) T cells to seek out and destroy cancer cells. T cells engineered to express CARs targeting the B cell antigen CD19 can induce durable remissions in many patients with refractory B cell neoplasms (13), and two CAR–T cell products have recently been approved by the U.S. Food and Drug Administration to treat B cell leukemia and lymphoma. Despite these successes in hematological cancers, CAR–T cell activity against solid tumors has been limited. On page 162, Ma et al. (4) describe a platform that uses a vaccine-boosting strategy to improve the efficacy of CAR–T cells to target solid tumors.